Entrectinib is a new generation inhibitor of multiple targets, such as neurotrophic tyrosine kinase, receptor type 1, neurotrophic tyrosine kinase, receptor type 2, neurotrophic tyrosine kinase, receptor type 3, ROS proto-oncogene 1 (ROS1), and ALK which has been approved in NRK and ROS1 positive NSCLC [52-54]. This evidence concerns the gene ALK and non-small cell lung carcinoma.